PARAMETERS FAVORABLE TO INTRAPROSTATIC RADIATION DOSE ESCALATION IN MEN WITH LOCALIZED PROSTATE CANCER

被引:31
|
作者
Housri, Nadine [1 ]
Ning, Holly [1 ]
Ondos, John [1 ]
Choyke, Peter [2 ]
Camphausen, Kevin [1 ]
Citrin, Deborah [1 ]
Arora, Barbara [1 ]
Shankavaram, Uma [1 ]
Kaushal, Aradhana [1 ]
机构
[1] NCI, Radiat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 80卷 / 02期
基金
美国国家卫生研究院;
关键词
IMRT; Prostate cancer; Dose escalation; Radiotherapy; Treatment planning; INTENSITY-MODULATED RADIOTHERAPY; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; SIMULTANEOUS INTEGRATED BOOST; DISTANT METASTASES; TUMOR-CONTROL; 90; GY; MRI; IMRT; TOXICITY; LESIONS;
D O I
10.1016/j.ijrobp.2010.06.050
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To identify, within the framework of a current Phase I trial, whether factors related to intraprostatic cancer lesions (IPLs) or individual patients predict the feasibility of high-dose intraprostatic irradiation. Methods and Materials: Endorectal coil MRI scans of the prostate from 42 men were evaluated for dominant IPLs. The IPLs, prostate, and critical normal tissues were contoured. Intensity-modulated radiotherapy plans were generated with the goal of delivering 75.6 Gy in 1.8-Gy fractions to the prostate, with IPLs receiving a simultaneous integrated boost of 3.6 Gy per fraction to a total dose of 151.2 Gy, 200% of the prescribed dose and the highest dose cohort in our trial. Rectal and bladder dose constraints were consistent with those outlined in current Radiation Therapy Oncology Group protocols. Results: Dominant IPLs were identified in 24 patients (57.1%). Simultaneous integrated boosts (SIB) to 200% of the prescribed dose were achieved in 12 of the 24 patients without violating dose constraints. Both the distance between the IPL and rectum and the hip-to-hip patient width on planning CT scans were associated with the feasibility to plan an SIB (p = 0.002 and p = 0.0137, respectively). Conclusions: On the basis of this small cohort, the distance between an intraprostatic lesion and the rectum most strongly predicted the ability to plan high-dose radiation to a dominant intraprostatic lesion. High-dose SIB planning seems possible for select intraprostatic lesions. (C) 2011 Elsevier Inc.
引用
收藏
页码:614 / 620
页数:7
相关论文
共 50 条
  • [31] Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study
    Hanks, GE
    Schultheiss, TE
    Hanlon, AL
    Hunt, M
    Lee, WR
    Epstein, BE
    Coia, LR
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (03): : 543 - 550
  • [32] Should Elderly Prostate Cancer Patients with Comorbidity be Spared from Prostate Radiation Dose Escalation?
    Sundar, S.
    Walker, G.
    Pascoe, A.
    CLINICAL ONCOLOGY, 2016, 28 (03) : 227 - 228
  • [33] Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: a dose-escalation trial (DESTROY-4).
    Deodato, Francesco
    Ferro, Milena
    Bonome, Paolo
    Pezzulla, Donato
    Romano, Carmela
    Buwenge, Milly
    Cilla, Savino
    Morganti, Alessio Giuseppe
    Macchia, Gabriella
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (3) : 239 - 249
  • [34] Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial
    Denham, James W.
    Steigler, Allison
    Joseph, David
    Lamb, David S.
    Spry, Nigel A.
    Duchesne, Gillian
    Atkinson, Chris
    Matthews, John
    Turner, Sandra
    Kenny, Lizbeth
    Tai, Keen-Hun
    Gogna, Nirdosh Kumar
    Gill, Suki
    Tan, Hendrick
    Kearvell, Rachel
    Murray, Judy
    Ebert, Martin
    Haworth, Annette
    Kennedy, Angel
    Delahunt, Brett
    Oldmeadow, Christopher
    Holliday, Elizabeth G.
    Attia, John
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 (03) : 301 - 307
  • [35] Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer
    Chen, Lily
    Gannavarapu, Bhavani S.
    Desai, Neil B.
    Folkert, Michael R.
    Dohopolski, Michael
    Gao, Ang
    Ahn, Chul
    Cadeddu, Jeffrey
    Bagrodia, Aditya
    Woldu, Solomon
    Raj, Ganesh V.
    Roehrborn, Claus
    Lotan, Yair
    Timmerman, Robert D.
    Garant, Aurelie
    Hannan, Raquibul
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] Biologically effective dose and definitive radiation treatment for localized prostate cancer
    Sanpaolo, P.
    Barbieri, V.
    Genovesi, D.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 (08) : 732 - 738
  • [37] Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer
    D'Ambrosio, David J.
    Pollack, Alan
    Harris, Eleanor E. R.
    Price, Robert A.
    Verhey, Lynn J.
    Roach, Mack, III
    Demanes, D. Jeffrey
    Steinberg, Michael L.
    Potters, Louis
    Wallner, Paul E.
    Konski, Andre
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 70 (03): : 671 - 677
  • [38] Moderately hypofractionated dose escalation radiotherapy for localized prostate cancer, ESHYPRO: Results of a retrospective single-centre series evaluating safety and efficacy
    Quintin, K.
    Crehange, G.
    Graff, P.
    CANCER RADIOTHERAPIE, 2024, 28 (04): : 333 - 340
  • [39] Dose Escalation Using a Hypofractionated, Intensity-Modulated Radiation Therapy Boost for Localized Prostate Cancer: Preliminary Results Addressing Concerns of High or Low α/β Ratio
    Shridhar, Ravi
    Bolton, Sue
    Joiner, Michael C.
    Forman, Jeffrey D.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (03) : E52 - E57
  • [40] Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: A dose-escalation trial
    Ippolito, Edy
    Cellini, Numa
    Digesu, Cinzia
    Cilla, Savino
    Mantini, Giovanna
    Balducci, Mario
    Di Lallo, Alessandra
    Deodato, Francesco
    Macchia, Gabriella
    Massaccesi, Mariangela
    Mattiucci, Gian Carlo
    Tagliaferri, Luca
    Piermattei, Angelo
    Cuscuna, Daniele
    Morganti, Alessio G.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (01) : 87 - 92